Hypercalcemia is a condition in which the blood calcium concentration is high. Calcium is important for carrying out normal functions of organs, muscles, cells, and nerves. It has a role in blood clotting and bone health as well. Hypercalcemia can make it hard for the body to carry out its normal functions. Extremely high levels of calcium can be life-threatening. Excess parathyroid hormone (PTH) is the main cause of hypercalcemia. If the patient is symptomatic or if the calcium level is higher than 15 mg/dL, even in asymptomatic patients, treatment for hypercalcemia is required. Increased extracellular fluid clearance, reduced gastrointestinal (GI) absorption, and decreased bone resorption are the goals of treating hypercalcemia.
Market Dynamics
The increasing regulatory approvals for hypercalcemia drugs are expected to drive the market growth during the forecast period. For instance, in November 2021, Endo International plc, a pharmaceutical company, announced that the shipping of its calcitonin salmon injection, USP, multi-dose vials (2 mL) had begun by its Par Sterile Products business. Moreover, it started shipping following the final U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application. Par's calcitonin salmon injection is therapeutically equivalent to the MIACALCIN injection provided by Viatris Inc., a global pharmaceutical company. The injection is intended for the early treatment of hypercalcemic emergencies when a rapid reduction in serum calcium is needed, in combination with other appropriate agents.
Key features of the study:
- This report provides in-depth analysis of the global hypercalcemia treatment market , and provides market size (US$ million) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hypercalcemia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bayer AG, Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Amgen Inc., Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Pvt. Ltd., Apotex Inc., Crinetics Pharmaceuticals, Inc., Alkem Labs, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals, and Slate Run Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypercalcemia treatment market
Detailed Segmentation:
- Global Hypercalcemia Treatment Market, By Drug Type:
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- Global Hypercalcemia Treatment Market, By Indication:
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- Global Hypercalcemia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypercalcemia Treatment Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Bayer AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Novartis AG
- Reddy’s Laboratories Ltd.
- Amgen Inc.
- Viatris Inc. (Mylan N.V.)
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Actiza Pharmaceutical Pvt. Ltd.
- Apotex Inc.
- Crinetics Pharmaceuticals, Inc.
- Alkem Labs
- Torrent Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd.
- Hikma Pharmaceuticals
- Slate Run Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.
